{"id":564196,"date":"2021-09-17T19:12:01","date_gmt":"2021-09-17T19:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564196"},"modified":"2021-09-17T19:12:01","modified_gmt":"2021-09-17T19:12:01","slug":"sales-of-liveattenuated-vaccines-is-expected-to-surpass-a-valuation-of-us-14-bn-over-the-assessment-period","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sales-of-liveattenuated-vaccines-is-expected-to-surpass-a-valuation-of-us-14-bn-over-the-assessment-period_564196.html","title":{"rendered":"Sales of Live-attenuated Vaccines Is Expected to Surpass a Valuation of US$ 14 Bn Over The Assessment Period"},"content":{"rendered":"
\n
\"Sales<\/a><\/div>\n
\n
Respiratory Virus Vaccines Market<\/div>\n<\/div>\n<\/div>\n
According to the Fact.MR’s Study, Against the backdrop of the ongoing pandemic, demand for respiratory virus vaccines is expected to surge exponentially<\/div>\n

Award winning market research company has published a report on the global respiratory virus vaccines market. As per the study, R&D on respiratory vaccines<\/a> is focused on COVID-19 at the moment, however, the long-term outlook remains positive. Learning from the impact of COVID-19, governments around the globe are focusing on developing adequate treatment options for respiratory vaccines.<\/p>\n

With over 110 million active cases globally, pharmaceutical companies are racing against time to introduce potential vaccine candidates. Breakthroughs have manifested themselves in the form of three final products: the Pfizer-BioNTech COVID-19 vaccine, COVAXINTM <\/sup>and Covishield. While inoculation procedures are underway across Europe and North America, the aforementioned candidates are anticipated to knock on the doors of all continents in the current financial year.<\/p>\n

With worldwide supply chain disruptions experienced thraoughout 2020, leading manufacturers are seeking to diversify their supply chain bases. Since the past few decades, procurement from low-cost destinations comprised the primary expansion strategy for leading multinational firms. For instance, in 2020, Japan announced a US$ 2.2 billion fundraising to assist healthcare companies to shift their base away from China, followed by the US which deployed a similar tactic.<\/p>\n

Countries such as Thailand, India, Vietnam and other South East Asian countries are the preferred destinations. Such initiatives are expected to assist respiratory virus manufacturers to enhance their research & development capacities in the long-run.<\/p>\n

“The rapidly mutating nature of different virus species is leading to the emergence of numerous life-threatening respiratory diseases, with COVID-19 occupying center stage presently. This is prompting healthcare companies to augment their R&D capacities by initiating various clinical trials for new drug and vaccine candidates,” says a Fact.MR analyst.  <\/em><\/p>\n

 <\/p>\n

For more Insights into the Market, Request a Sample of this Report<\/strong><\/p>\n

https:\/\/www.factmr.com\/connectus\/sample?flag=S&rep_id=5199<\/strong><\/a> <\/strong><\/p>\n

 <\/p>\n

\"respiratory<\/p>\n

 <\/p>\n

Key Takeaways from Fact.MR’s Respiratory Virus Vaccines Market Study<\/strong><\/p>\n